Treatment of reactive hypoglycemia with macrobiotic Ma-Pi 2 diet as assessed by continuous glucose monitoring system

ISRCTN ISRCTN84079151
DOI https://doi.org/10.1186/ISRCTN84079151
Secondary identifying numbers 51/14
Submission date
02/02/2016
Registration date
05/02/2016
Last edited
29/04/2016
Recruitment status
No longer recruiting
Overall study status
Completed
Condition category
Nutritional, Metabolic, Endocrine
Prospectively registered
Protocol
Statistical analysis plan
Results
Individual participant data
Record updated in last year

Plain English summary of protocol

Background and study aims
Reactive hypoglycemia (RH) is a disorder where levels of glucose (sugar) in the blood become dangerously low following a meal (called hypoglycemic episodes). Nutritional therapy is recommended for people affected by RH. The macrobiotic Ma-Pi 2 diet is a nutritional therapy that improves glucose control in people with type 2 diabetes. The aim of this study is to investigate whether the Ma-Pi 2 diet improves blood glucose levels in patients affected by RH.

Who can participate?
Patients diagnosed with RH, aged 26 to 65.

What does the study involve?
Patients are randomly allocated to one of two groups. One group receives the control (low-glycemic index) diet for 3 days followed by the macrobiotic Ma-Pi 2 diet for a further 3 days. The other group receives the Ma-Pi 2 diet and then the control diet. All participants' blood glucose levels are measured throughout the study by using continuous glucose monitoring devices and glucometers.

What are the possible benefits and risks of participating?
There may be immediate direct benefits to the subjects participating - i.e. reduction of the number of hypoglycemic episodes. The main risk could be a drastic decrease in glucose levels and to avoid it participants will be strictly monitored by the doctors and specialists involved.

Where is the study run from?
The Endocrinology Area of the University of Campus Biomedico of Rome (Italy).

When is the study starting and how long is it expected to run for?
February 2014 to February 2015

Who is funding the study?
UPM Un Punto Macrobiotico International Association (Italy)

Who is the main contact?
1. Professor Paolo Pozzilli (p.pozzilli@unicampus.it)
2. Dr Andreea Soare (a.soare@unicampus.it)

Contact information

Prof Paolo Pozzilli
Scientific

Via Alvaro del Portillo 21
Rome
00128
Italy

Phone +39 (0)6 22541 9184
Email p.pozzilli@unicampus.it

Study information

Study designInterventional crossover single-centre trial
Primary study designInterventional
Secondary study designRandomised cross over trial
Study setting(s)Other
Study typeTreatment
Participant information sheet Not available in web format, please use the contact details below to request a patient information sheet
Scientific titleA randomized crossover trial to assess the effect of the Ma-Pi 2 MAcrobiotic diet in the treatment of reactive HYPoglycemia with continuous glucose monitoring system (MAHYP)
Study acronymMAHYP
Study objectivesThis study is designed to determine whether short-term administration of the macrobiotic Ma-Pi 2 diet improves metabolic control in non-diabetic subjects affected by reactive hypoglycemia (reduction of the number of hypoglycemic episodes and assessment of glycemic distributions through different readings by continuous glucose monitoring system) compared with a low-GI diet for reactive hypoglycemia – to date, there is no diet for treating this condition.

The null hypothesis is that there will be no reduction of the number of hypoglycemic episodes or that there will be no difference according to the dietary sequence administered.
Ethics approval(s)The Ethics Committee of the University Campus Bio-Medico of Rome, 30/09/2014, prot. 51/14
Health condition(s) or problem(s) studiedReactive hypoglycemia
InterventionThe subjects enrolled in the study are randomized and consequently divided into two homogeneous groups to receive the two dietary treatments in opposite sequence. Over a period of 6 days they are lodged in a farm in Italy, where they receive all daily meals (Ma-Pi 2 Macrobiotic meals or a control low-GI diet for reactive hypoglycemia).
Anthropometrical measurements will be carried out at baseline and after 6 days of the dietary interventions. Glucose profile measurements will be performed throughout the trial by using continuous glucose monitoring and glucometers.
Intervention typeOther
Primary outcome measureReduction of the number of episodes of reactive hypoglycemia (blood glucose level below 70 mg/dL) in patients affected by such condition during macrobiotic Ma-Pi 2 diet administration compared to a same period during the administration of a low-GI diet.
Secondary outcome measuresGlycemic distributions assessment through different readings (< 40; 41-50; 51-60; 61-70, 71-80, 81-90, 91-100, 101-110, 111-120, 121-130, 131-140, 141-150, 151-160, 161-170, 171-180 and > 180 mg/dL), measured and compared between the two dietary treatments
Overall study start date01/10/2014
Completion date28/02/2015

Eligibility

Participant type(s)Patient
Age groupAdult
Lower age limit18 Years
SexBoth
Target number of participants12
Key inclusion criteria1. Non-diabetic patients
2. Both sexes
3. Aged at least 18 years old
4. BMI between 18 and 35 kg/m2
5. Able to provide written informed consent and to follow the procedures of the protocol
6. Previous diagnosis of RH, though it was confirmed by MMT before the enrolment
Key exclusion criteria1. Impaired fasting glucose/impaired glucose tolerance/diabetic patients
2. Subjects affected by insulinoma or by other hypoglycemic endocrine conditions
3. Patients affected by any neoplasia
4. Patients affected by any food behavior disorders
5. Pregnant women
6. Symptoms of hypocalcemia
7. Known or suspected hypersensitivity to any of the ingredients of the administered diets
8. Patients under vitamin K antagonists or corticosteroid treatment
9. Subjects under any drugs therapy which might interfere with glucose metabolism
Date of first enrolment01/10/2014
Date of final enrolment31/01/2015

Locations

Countries of recruitment

  • Italy

Study participating centre

Campus Bio-Medico University of Rome
Via Alvaro del Portillo 21
Rome
00128
Italy

Sponsor information

UPM Un Punto Macrobiotico International Association (Italy)
Charity

Via San Nicola 9
Tolentino
62029
Italy

Phone +39 (0)7 3396 1019
Email upm@unpuntomacrobiotico.com

Funders

Funder type

Charity

UPM Un Punto Macrobiotico International Association (Italy)

No information available

Results and Publications

Intention to publish date31/03/2016
Individual participant data (IPD) Intention to shareYes
IPD sharing plan summaryAvailable on request
Publication and dissemination planWe wish to publish our results as soon as possible
IPD sharing plan